Table 4.

Clinicopathologic characteristics of PIK3CA mutated tumors by mutation subtype.

Characteristic		KD mutation (N = 35)	HD mutation (N= 44)	P value*
		N (%)	N (%)
Age
≤ 50		11 (31%)	13 (30%)
> 50		24 (69%)	27 (61%)	0.92
Unknown		0 (0%)	4 (10%)
Menopausal status
Pre		10 (29%)	8 (18%)
Post		11 (31%)	15 (34%)	0.39
Unknown		14 (40%)	21 (47%)
Race
Caucasian		30 (86%)	41 (93%)
Black		2 (6%)	1 (2%)
Asian/Pacific Islander		0 (0%)	0 (0%)	0.58
Unknown or other		3 (9%)	2 (5%)
Tumor size
0 –2 cm		8 (23%)	10 (23%)
2.1 –5 cm		9 (26%)	10 (23%)
> 5 cm		2 (6%)	1 (5%)	0.9
Unknown or NA		16 (46%)	23 (53%)
Histologic subtype
Ductal		32 (91%)	40 (93%)
Lobular		2 (6%)	2 (5%)
Other		1 (3%)	1 (2%)	1
Grade
Low		10 (29%)	7 (16%)
Intermediate		18 (51%)	24 (55%)
High		7 (20%)	12 (27%)	0.39
Unknown or NA		0 (0%)	1 (2%)
Positive lymph nodes
0		16 (46%)	16 (36%)
1 –3		6 (17%)	14 (32%)
> 3		9 (26%)	6 (14%)	0.18
Unknown or NA		4 (11%)	8 (18%)
ER
Postive		30 (86%)	36 (82%)
Negative		3 (9%)	5 (11%)	0.73
Unknown		2 (6%)	4 (9%)
PR
Positive		29 (83%)	27 (61%)
Negative		4 (11%)	13 (30%)	0.04
Unknown		2 (6%)	4 (9%)
HER2
Positive		2 (6%)	4 (9%)
Negative		31 (89%)	31 (70%)	0.133
Unknown		2 (6%)	9 (20%)
Receptor status
ER+ or PR+/HER2−		30 (86%)	26 (59%)
ER+ or PR+/HER2+		0 (0%)	3 (7%)
ER−and PR−/HER2+		2 (6%)	0 (0%)
ER−and PR−/HER2−		1 (3%)	5 (11%)
Other		2 (6%)	10 (23%)	0.008
Recurrent disease
yes		22 (63%)	39 (89%)
no		12 (37%)	5 (11%)	0.007
Metastatic at diagnosis
yes		6 (17%)	9 (20%)
no		29 (83%)	35 (80%)	0.71
Unknown		0 (0%)	0 (0%)

Note: "Unknown," "other," or "NA" not included in p value calculation.

KD = kinase domain, HD = helical domain